Clinical Trial

A Study of LAD603 in Adults With Alopecia Areata

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Protocol Amendment History 1 change
notable Primary completion pushed: 2027-05-23 -> 2027-06-23 2026-05-21
Trial Details
NCT Number NCT07311564
Lead Sponsor Almirall, S.A.
Conditions Alopecia Areata
Enrollment 136 participants
Start Date 2025-12-17
Primary Completion 2027-06-23 (estimated)
Study Completion 2027-11-21 (estimated)
Updated on ClinicalTrials.gov 2026-05-20